The biotechnology company Erasca surprises with continuous [good news] — Stock poised for breakout from base!

Erasca, based in the USA, specializes in the development of precision oncology therapies aimed at blocking the RAS/MAPK signaling pathway in cancer cells. Analysts regard 2026 as the most important and catalyst-rich year in the company's history. On March 18, JPMorgan raised the price target for the stock from $24 to $25, which still represents a potential of over 50%, despite the spectacular rally of recent months. In early January 2026, there were significant advancements regarding an extended patent protection for ERAS-0015, a so-called Pan-RAS...